BioMarin Pharmaceutical has announced it will acquire Amicus Therapeutics in an all-cash deal valued at $4.8 billion. The acquisition is part of BioMarin’s strategy to strengthen its portfolio in rare diseases after recent business restructuring and asset cuts.
According to BioMarin, the purchase prices Amicus shares at $14.50 each, which represents a 33% premium over the company’s most recent closing price. Following the announcement on Friday morning, BioMarin’s stock rose by 4.6% to $54.34 in pre-market trading.
Through this transaction, BioMarin will add two FDA-approved drugs to its offerings: Galafold, used for Fabry disease, and Pombiliti/Opfolda, a combination therapy for Pompe disease. The acquisition also includes U.S. rights to DMX-200, a Phase III investigational treatment for focal segmental glomerulosclerosis, a rare kidney disorder.
BioMarin stated that the addition of Amicus is expected to “accelerate revenue growth” for the company. Combined sales of Galafold and Pombiliti/Opfolda reached $599 million over the past year for Amicus.
The move comes after BioMarin previously set a target of reaching $4 billion in annual revenue by 2027 without factoring in mergers or acquisitions. However, by October 2025, the company reduced its guidance due to lower-than-expected sales from Voxzogo, its achondroplasia therapy. In 2024, Voxzogo generated $735.1 million in revenue and was second only to Vimizim—used for mucopolysaccharidosis—which brought in $739.8 million that year.
When updating investors about missing its revenue goal, BioMarin also announced it would divest from Roctavian, its hemophilia A treatment that had not met sales expectations despite being one of three newly created business units following restructuring efforts in late 2024.
This decision followed another portfolio reduction earlier in August when BioMarin discontinued work on a preclinical phenylketonuria program.
Amicus marks BioMarin’s second major acquisition this year; earlier in May, it purchased Inozyme for $270 million. The main product from Inozyme—INZ-701—is still early in development but is intended as a treatment for ENPP1 deficiency and recently completed Phase I/II trials before advancing toward later-stage studies.
